GlassScriptPhysician profile
Saima A Zafar
NPI 1437131273
$3,531.43
in general payments reported to CMS, 2019-2025
21 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $133 · 2022: $12.17 · 2023: $2,087 · 2024: $418 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051 · Travel and Lodging: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.40 |
| Travel and Lodging | $1,133.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,558.86 | 2023-2025 | Venaseal, Reveal Linq, Linq II |
| Altathera Pharmaceuticals LLC | $348.47 | 2023 | Sotalol Hydrochloride |
| Cvrx, INC. | $223.93 | 2024 | Barostim Neo System |
| Novo Nordisk INC | $175.35 | 2023-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.38 | 2019-2023 | Lifevest |
| Cleerly, INC. | $144.71 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Pfizer INC. | $133.30 | 2020-2024 | |
| Amarin Pharma, INC. | $129.95 | 2019-2020 | |
| Boston Scientific Corporation | $128.01 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $119.78 | 2023-2025 | Verquvo |
| Amgen INC. | $103.65 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $94.92 | 2019-2024 | |
| Abbott Laboratories | $58.13 | 2025 | Jot Dx |
| Heartflow, INC. | $29.86 | 2025 | |
| Philips North America LLC | $29.59 | 2022-2025 | Extended Holter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.88 | 2025 | Eliquis |
| Edwards Lifesciences Corporation | $25.81 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $14.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.96 | 2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $12.25 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $9.95 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.